Business
Clarity signs copper-67 Supply Agreement with Nusano
Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a Supply Agreement for copper-67 with Nusano, Inc. ("Nusano").
About this update from Clarity Pharmaceuticals Ltd.
[{"type":"text","content":"SYDNEY, Oct. 16, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a Supply Agreement for copper-67 with Nusano, Inc. ("Nusano").","length":383,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Clarity Pharmaceuticals)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Clarity Pharmaceuticals)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":98,"url":"https://media.zenfs.com/en/prnewswire.com/2ced23e8ddb3b1ec6ef537b99f6e12a7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fkXRk3krOQ3AG6qYDObpxg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE3MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/2ced23e8ddb3b1ec6ef537b99f6e12a7","width":400,"height":98}},"href":"https://mma.prnewswire.com/media/1700068/Clarity_Large_Logo_high_res_ID_42691c6bc5c0_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Nusano's 190,000 square foot state-of-the-art facility in West Valley City, Utah is expected to begin operations in late 2025 with copper-67 isotope supply planned to commence in mid-2026. The proprietary accelerator-based technologies employed by Nusano are particularly well suited for high-volume mass production of copper-67. Nusano is uniquely positioned to regularly supply this therapeutic isotope for both Clarity's clinical trials and commercial use based on the ease of production and readily available target material. Importantly, Nusano is setting up its own enriched stable isotope production for copper-67 starting materials in the near future, further reducing supply chain risks while allowing for a fully integrated production process in the United States.","length":782,"tagName":"p"},{"type":"text","content":"The copper-67 supply from Nusano further expands Clarity's growing network of US-based suppliers, including NorthStar Medical Radioisotopes, LLC ("NorthStar") and Idaho State University Idaho Accelerator Center (IAC).","length":236,"tagName":"p"},{"type":"text","content":"Dr Alan Taylor, Executive Chairperson of Clarity Pharmaceuticals, commented: "We are excited to continue growing...